CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1187953 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY-25.4%
TTM EPS YoY29.9%
Revenue 3-yr CAGR-50.4%
Net income 3-yr CAGR—
Margins
Gross margin66.9%
Operating margin-256,435.0%
Net margin-249,160.1%
FCF margin—
EBITDA margin—
Returns
ROE-119.2%
ROA-113.8%
ROIC (approx.)-3,736.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.0%
Debt / equity0.00x
Current ratio23.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-16.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6,000 | $11,000 |
| Cost of revenue | $2,194 | $4,400 |
| Gross profit | $3,806 | $6,600 |
| R&D expense | $2.26M | $2.40M |
| SG&A expense | $3.76M | $3.24M |
| Operating income | -$6.14M | -$5.74M |
| Pretax income | -$6.00M | -$5.49M |
| Income tax | $0 | $0 |
| Net income | -$6.00M | -$5.49M |
| EBITDA | — | -$5.69M |
| EPS (diluted) | -2.52 | -3.71 |
| Weighted avg. shares (diluted) | 2.38M | 1.48M |
| Balance sheet | ||
| Cash & equivalents | $7.21M | $5.94M |
| Inventory | $0 | $2,194 |
| Current assets | $7.40M | $6.14M |
| Intangibles | $407,230 | $530,559 |
| Total assets | $7.81M | $6.67M |
| Current liabilities | $284,880 | $327,644 |
| Total liabilities | $284,880 | $327,644 |
| Shareholders' equity | $7.51M | $6.34M |
| Shares outstanding | 3.70M | 1.75M |
| Cash flow statement | ||
| Operating cash flow | -$5.86M | -$5.30M |
| Investing cash flow | -$50,500 | $6.32M |
| Financing cash flow | $7.17M | $1.45M |
| Depreciation & amortization | — | $56,000 |
| Stock-based compensation | $3,485 | $36,648 |
| Share buybacks | $10,000 | $174,964 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.